vialaudit
pt-141 · north carolina

Is PT-141 legal in North Carolina?

status · caveats apply
FDA-approved as Vyleesi (NDA 210557, June 21 2019) for HSDD; 'PT-141 research peptide' from retail vendors is unauthorized diversion of an approved drug. No state-level peptide restrictions beyond federal law in North Carolina.

category: approved drug diversion · last verified May 13, 2026

§ 01

Quick answer

FDA-approved as Vyleesi (NDA 210557, June 21 2019) for HSDD; 'PT-141 research peptide' from retail vendors is unauthorized diversion of an approved drug. No state-level peptide restrictions beyond federal law in North Carolina.
§ 02

Full status breakdown

Federal status

FDA approval
approved as drug · brand: Vyleesi · NDA 210557 · approved Jun 21, 2019
Indications: acquired generalized hypoactive sexual desire disorder (HSDD) in premenopausal women
DEA scheduling
not scheduled
503A compounding
Bulks list: not on list
Do-not-compound list: not on list
Not eligible for §503A bulk compounding (approved drug). Not on Cat 2.
FDA Warning Letters
none on record for this compound
Shortage status
not currently on shortage list
Sale framing
Research-use-only posture: CRITICAL CROSS-REFERENCE: PT-141 = bremelanotide = Vyleesi. Every 'PT-141 research peptide' sold by a research-chemical vendor is chemically the same compound as Vyleesi. This is unauthorized diversion of an approved drug, not a legal 'research peptide' gray area.
Personal possession: Not federally criminalized; state laws may vary.

North Carolina — state-specific

Sport-body status

WADA 2026
not on prohibited list
Not explicitly named.
USADA
unknown
NCAA
unknown

What we couldn’t verify

§ 03

Also known as

PT-141 is also marketed or referenced under the following names (vendor pseudonyms, brand names, chemical identifiers):

  • Bremelanotide
  • Vyleesi
  • PT141
  • NDA 210557
  • Palatin bremelanotide
§ 04

Disclaimer

§ 05

Related

the roundup · monthly

Receipts in your inbox. Once a month.

New audits, expired coupons pruned, lab notes from vials still on the bench. No marketing. No lifestyle copy. Unsubscribe in one click.

14,200 subscribers· 0 sponsored items· 11 issues since launch